![](https://endpts.com/wp-content/uploads/2021/10/Carsten-Brunn-Selecta-Biosciences-tile-scaled.jpg)
Carsten Brunn, Cartesian Therapeutics CEO
Cartesian clears an autoimmune CAR-T trial, starts another Phase 2 and raises $130M
Cartesian Therapeutics, an mRNA cell therapy biotech, said its lead investigational medicine helped patients with an autoimmune condition that has caught the attention of many …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.